25 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Article Searches
Regeneron (REGN) Gets FDA Nod for Praluent Label Extension https://www.zacks.com/stock/news/2239502/regeneron-regn-gets-fda-nod-for-praluent-label-extension?cid=CS-ZC-FT-analyst_blog|earnings_article-2239502 Mar 12, 2024 - Regeneron (REGN) obtains FDA approval for Praluent as an adjunct to diet and other LDL-C, lowering therapies to include pediatric patients aged eight and older with HeFH.
ASLAN (ASLN) Up 161% on Upbeat Initial Data From Eczema Study https://www.zacks.com/stock/news/2239307/aslan-asln-up-161-on-upbeat-initial-data-from-eczema-study?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2239307 Mar 12, 2024 - ASLAN (ASLN) rises on upbeat initial data from a phase II study of eblasakimab in patients with eczema, who have previously been treated with Dupixent but did not achieve an adequate response.
Top Analyst Reports for Microsoft, Amazon.com & Berkshire Hathaway https://www.zacks.com/commentary/2230125/top-analyst-reports-for-microsoft-amazon-com-berkshire-hathaway?cid=CS-ZC-FT-research_daily-2230125 Feb 22, 2024 - Today's Research Daily features new research reports on 16 major stocks, including Microsoft Corporation (MSFT), Amazon.com, Inc. (AMZN) and Berkshire Hathaway Inc. (BRK.B).
Pharma Stock Roundup: PFE, MRK, NVO & SNY's Q4 Earnings, FDA Updates https://www.zacks.com/stock/news/2220214/pharma-stock-roundup-pfe-mrk-nvo-sny-s-q4-earnings-fda-updates?cid=CS-ZC-FT-analyst_blog|stock_roundup-2220214 Feb 02, 2024 - Pfizer (PFE), Merck (MRK), Novartis (NVS), Novo Nordisk (NVO) and Sanofi (SNY) announce fourth-quarter and full-year 2023 results.
Sanofi (SNY) Q4 2023 Earnings Call Transcript https://www.fool.com/earnings/call-transcripts/2024/02/01/sanofi-sny-q4-2023-earnings-call-transcript/?source=iedfolrf0000001 Feb 01, 2024 - SNY earnings call for the period ending December 31, 2023.
TEVA Q4 Earnings and Revenues Surpass Estimates, Stock Up https://www.zacks.com/stock/news/2219707/teva-q4-earnings-and-revenues-surpass-estimates-stock-up?cid=CS-ZC-FT-analyst_blog|earnings_article-2219707 Feb 01, 2024 - TEVA reports better-than-expected fourth-quarter results, beating both earnings and sales estimates. The stock gains 3% in response.
Sanofi (SNY) Misses on Q4 Earnings and Sales, Stock Down https://www.zacks.com/stock/news/2219619/sanofi-sny-misses-on-q4-earnings-and-sales-stock-down?cid=CS-ZC-FT-analyst_blog|earnings_article-2219619 Feb 01, 2024 - Sanofi (SNY) misses fourth-quarter estimates for earnings and sales. It maintains 2024 earnings growth guidance.
Why Sanofi (SNY) Might Surprise This Earnings Season https://www.zacks.com/stock/news/2218829/why-sanofi-sny-might-surprise-this-earnings-season?cid=CS-ZC-FT-tale_of_the_tape|earnings_surprise-2218829 Jan 31, 2024 - Sanofi (SNY) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Biotech Stock Roundup: GILD Down on Study Results, INBX Gains on Sanofi Deal & More https://www.zacks.com/stock/news/2215085/biotech-stock-roundup-gild-down-on-study-results-inbx-gains-on-sanofi-deal-more?cid=CS-ZC-FT-analyst_blog|stock_roundup-2215085 Jan 24, 2024 - Gilead Sciences (GILD) and Inhibrx (INBX) are in the spotlight on regulatory and pipeline updates.
Inhibrx (INBX) Up 6% on Sale of Rare Disease Drug to Sanofi https://www.zacks.com/stock/news/2214518/inhibrx-inbx-up-6-on-sale-of-rare-disease-drug-to-sanofi?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2214518 Jan 23, 2024 - Sanofi (SNY) will acquire Inhibrx (INBX) for nearly $2.2 billion. Post-acquisition, it will retain the rare disease drug and spin out all other pipeline programs into a newly-traded public company.

Pages: 123

Page 1>